Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

COPD Patients Improve in Trial of Imidafenacin

Key clinical point: The oral drug imidafenacin shows promise in a phase 2 trial in chronic obstructive pulmonary disease (COPD).

Major finding: In patients who took the drug, maximum change in FEV1 significantly improved over 24 hours vs. placebo.

Study details: Multicenter, randomized, double-blind 3×3 crossover Phase 2 trial of a single dose of oral imidafenacin (0.1 mg or 0.2 mg) vs. placebo in 27 male patients with COPD.

Disclosures: Ono Pharmaceutical funded the study. The authors report various disclosures.